DNA Damage and Repair 2

• 1735 · PDF Expanding the therapeutic potential of TXNRD inhibitors for triple-negative breast cancer Brenna Flowers, Abigail Rullo, An Zhang, Iria Lloshi, Keacha Chang, Valentina Petukhova, Pavel A. Petukhov, Irida Kastrati
• 1736 · PDF Synergistic anticancer activity of ciclopirox and prexasertib in non-small cell lung cancer cells Zhu Huang, Bing Cheng, Shile Huang
• 1737 Direct measurement of NER activity using sSTRIDE-NER Olga Wójcikowska, Julita Imioło, Magdalena Bartyńska, Zsombor Prucsi, Magdalena Kordon-Kiszala, Kamil Solarczyk
• 1738 · PDF Alnodesertib (ART0380) in combination with irinotecan is highly efficacious in preclinical models of ATM null pancreatic cancer Helen M. R. Robinson, Elias Elinati, Eeson Rajendra, Paula Costales, Aurora Cerutti, Lerin Geo, Emily Graham, Kirsty Lawrence, Joana F. B. P. Neves, Marina Roy-Luzarraga, Ozgun Ozer, Vera Grinkevich, Jayesh B. Majithiya, Ian Smith, Graeme C. Smith
• 1739 · PDF Deciphering the molecular links between DNA damage response and autophagy in cancer: Implications for chemotherapy resistance Kavya Ajit Pandya, Neeru Singh
• 1740 · PDF Quantitative helicase and polymerase assays to accelerate DNA damage repair targeted drug development Oganinma Okakpu, Kasia Zientara-Rytter, Veronique Baron, Michelle Kinbara, Guillermo Cardenas, Jonathan Mikolosko, Henry Zhu, Pavel Shashkin
• 1741 · PDF Nanoparticle co-delivery of microtubule inhibitors and cisplatin overcomes DNA repair-mediated resistance in head and neck cancer Xin Li, Liubov Palchak, Ling Wang, Marina Sokolsky, Alexander Kabanov, Aimin Peng
• 1743 · PDF A novel brain-penetrant dual ATR-mTOR inhibitor for PTEN-deficient cancers Sarah Truong, Beibei Zhai, Louise Ramos, Mona Marzban, Fariba Ghaidi, Marshall Drew-Brook, Peter Guzzo, Ahmad Issa, Mehran Khodabandeh, Sara Omar, Jason Rolfe, Seyed A. Saberali, Kally Singh, John Langlands, Dennis Brown, Jeffrey Bacha, Mads Daugaard
• 1744 CRISPR screening identifies SMARCAL1 and MRN as modulators of WRN dependency in MSI-H colorectal cancer Tiantian Ma, Jibo Wu, Siting Li, Junjie Chen
• 1746 · PDF Dual inhibition of TREX1 and polymerase theta uncovers a synergistic DNA repair vulnerability in BRCA-deficient tumors Roger Shen, Daniel S Higginson
• 1747 A combination of PG3 and PARP inhibitors exhibits antitumor effects in both BRCA1-mutated and BRCA1-wild-type TNBC Xiaobing Tian, Wafik S. El-Deiry
• 1748 · PDF FORX-428: Exploiting PARG inhibition to target replication stress in cancer cells Frank Tadashi Zenke, Ulrich Lücking, Olivier Querolle, Luca Iacovino, Marta Malattia, Alessandro Potenza, Nicolas Bocquet, Serena Bologna, Hanna Kok, Anika Kuster, Roxanne Lourman, Jason Clochard, Irena Konstantinova, Thanos D. Halazonetis, Jens Wuerthner, Tarig Bashir
• 1749 · PDF Modeling response to alkylating chemotherapy in a syngeneic model of MGMT overexpression and MMR-deficient glioma Ranjini K. Sundaram, Deepti Bhatt, Ranjit S. Bindra, Juan Vasquez
• 1750 · PDF Building an integrated platform for drug discovery in DNA damage response Bruno Vaz, Julien Brustel, Marie Cargnello, Marie Lafitte, Frédérique Dol-Gleizes, Rahul Valiya Veettil, Andrei Zinovyev, Anne-Sophie Casagrande, Francisco H. Cruzalegui, Stephen Durant
• 1751 · PDF Deletion of the DACH1 gene tumor suppressor increases replication fork stress, epithelial mesenchymal transition and sensitivity to WEE1 kinase inhibitors in prostate cancer Danni Li, Arijit Ghosh, Zhiping Li, Kenneth Iczkowski, Hidetoshi Mori, Samiha Nasser, Csaba Kerepesi, Andras Benczur, Hallgeir Rui, Ritika Harish, Li Lan, Xuanmao Jiao, Fred Saad, Janne Purhonen, Anthony W. Ashton, Richard G. Pestell
• 1752 · PDF APOBEC3B enhances PARP inhibitor response by suppressing ovarian cancer stem cells Maria Rivera, Lucy Liu, Chae-Eun Lim, Sabina Enlund, Haoran Zhang, Kaifu Yang, Roman Sasik, Kathleen Fisch, Frida Holm, Leslie A. Crews, Qingfei Jiang

在完整检索应用中浏览本分会场 →